Niagen Bioscience (OCD1) Ratios
Niagen Bioscience Ratios
DE:OCD1's free cash flow for Q2 2026 was $2.68M. For the 2026 fiscal year, DE:OCD1's free cash flow was decreased by $-89.00K and operating cash flow was $2.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 |
| Quick Ratio | 3.83 | 3.06 | 1.70 | 1.78 | 2.00 |
| Cash Ratio | 3.25 | 2.48 | 1.32 | 1.14 | 1.59 |
| Solvency Ratio | 0.63 | 0.45 | -0.12 | -0.58 | -0.98 |
| Operating Cash Flow Ratio | 0.67 | 0.67 | 0.35 | -0.84 | -1.37 |
| Short-Term Operating Cash Flow Coverage | 13.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 66.93M | $ 41.92M | $ 23.03M | $ 21.18M | $ 22.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.04 | 0.06 | 0.08 | 0.08 |
| Debt-to-Equity Ratio | 0.04 | 0.06 | 0.12 | 0.15 | 0.15 |
| Debt-to-Capital Ratio | 0.04 | 0.05 | 0.10 | 0.13 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.39 | 1.48 | 1.93 | 1.89 | 1.82 |
| Debt Service Coverage Ratio | 18.79 | 0.00 | 0.00 | 0.00 | -462.67 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -492.24 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.03 | 0.05 | 0.06 | 0.07 |
| Net Debt to EBITDA | -3.16 | -4.05 | 6.14 | 0.96 | 0.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 64.28% | 61.84% | 60.76% | 59.40% | 61.51% |
| EBIT Margin | 14.06% | 8.89% | -6.70% | -25.85% | -40.14% |
| EBITDA Margin | 15.18% | 10.38% | -4.66% | -23.24% | -37.73% |
| Operating Profit Margin | 11.05% | 7.76% | -6.70% | -25.85% | -40.14% |
| Pretax Profit Margin | 14.06% | 8.89% | -5.91% | -22.96% | -40.22% |
| Net Profit Margin | 13.43% | 8.58% | -5.91% | -22.96% | -40.22% |
| Continuous Operations Profit Margin | 13.43% | 8.58% | -5.91% | -22.96% | -40.22% |
| Net Income Per EBT | 95.55% | 96.56% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 127.25% | 114.61% | 88.19% | 88.79% | 100.20% |
| Return on Assets (ROA) | 16.34% | 12.52% | -8.98% | -30.60% | -46.90% |
| Return on Equity (ROE) | 22.71% | 18.55% | -17.35% | -57.69% | -85.50% |
| Return on Capital Employed (ROCE) | 16.53% | 15.35% | -16.30% | -51.48% | -67.30% |
| Return on Invested Capital (ROIC) | 15.61% | 14.53% | -15.98% | -50.50% | -66.40% |
| Return on Tangible Assets | 17.25% | 12.59% | -9.07% | -30.98% | -47.61% |
| Earnings Yield | 3.45% | 1.88% | -4.90% | -14.29% | -10.80% |
| Efficiency Ratios | |||||
| Receivables Turnover | 13.29 | 12.82 | 15.97 | 8.49 | 12.91 |
| Payables Turnover | 4.28 | 4.46 | 3.20 | 3.02 | 2.49 |
| Inventory Turnover | 2.26 | 4.14 | 2.26 | 1.99 | 1.91 |
| Fixed Asset Turnover | 36.82 | 28.88 | 18.42 | 11.40 | 9.17 |
| Asset Turnover | 1.22 | 1.46 | 1.52 | 1.33 | 1.17 |
| Working Capital Turnover Ratio | 2.10 | 2.65 | 2.90 | 2.40 | 2.87 |
| Cash Conversion Cycle | 103.48 | 34.86 | 70.65 | 105.33 | 72.97 |
| Days of Sales Outstanding | 27.47 | 28.47 | 22.86 | 42.97 | 28.28 |
| Days of Inventory Outstanding | 161.24 | 88.27 | 161.68 | 183.13 | 191.24 |
| Days of Payables Outstanding | 85.23 | 81.87 | 113.90 | 120.77 | 146.55 |
| Operating Cycle | 188.71 | 116.73 | 184.54 | 226.10 | 219.52 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.17 | 0.14 | 0.10 | -0.22 | -0.36 |
| Free Cash Flow Per Share | 0.17 | 0.14 | 0.10 | -0.22 | -0.37 |
| Dividend Paid and CapEx Coverage Ratio | 46.02 | 74.29 | 48.09 | -45.20 | -59.08 |
| Capital Expenditure Coverage Ratio | 46.02 | 74.29 | 48.09 | -45.20 | -59.08 |
| Operating Cash Flow Coverage Ratio | 4.77 | 4.57 | 2.17 | -3.55 | -5.14 |
| Operating Cash Flow to Sales Ratio | 0.10 | 0.12 | 0.09 | -0.21 | -0.36 |
| Free Cash Flow Yield | 2.61% | 2.63% | 6.91% | -13.33% | -9.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 28.91 | 53.10 | -20.43 | -7.00 | -9.26 |
| Price-to-Sales (P/S) Ratio | 3.89 | 4.55 | 1.21 | 1.61 | 3.73 |
| Price-to-Book (P/B) Ratio | 6.58 | 9.84 | 3.54 | 4.04 | 7.92 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 38.31 | 37.97 | 14.48 | -7.50 | -10.23 |
| Price-to-Operating Cash Flow Ratio | 37.48 | 37.46 | 14.17 | -7.67 | -10.40 |
| Price-to-Earnings Growth (PEG) Ratio | 0.29 | -0.22 | 0.29 | 0.17 | -0.44 |
| Enterprise Value Multiple | 22.48 | 39.82 | -19.77 | -5.96 | -8.96 |
| Enterprise Value | 441.60M | 411.74M | 76.98M | 99.75M | 227.96M |
| EV to EBITDA | 22.48 | 39.82 | -19.77 | -5.96 | -8.96 |
| EV to Sales | 3.41 | 4.13 | 0.92 | 1.38 | 3.38 |
| EV to Free Cash Flow | 33.59 | 34.47 | 11.05 | -6.46 | -9.28 |
| EV to Operating Cash Flow | 32.86 | 34.00 | 10.82 | -6.61 | -9.43 |
| Tangible Book Value Per Share | 0.90 | 0.54 | 0.40 | 0.41 | 0.46 |
| Shareholders’ Equity Per Share | 0.97 | 0.54 | 0.40 | 0.42 | 0.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | 0.03 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.63 | 1.17 | 1.18 | 1.05 | 1.00 |
| Net Income Per Share | 0.22 | 0.10 | -0.07 | -0.24 | -0.40 |
| Tax Burden | 0.96 | 0.97 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.88 | 0.89 | 1.00 |
| Research & Development to Revenue | 0.05 | 0.06 | 0.06 | 0.07 | 0.06 |
| SG&A to Revenue | 0.48 | 0.48 | 0.30 | 0.39 | 0.54 |
| Stock-Based Compensation to Revenue | 0.05 | 0.04 | 0.06 | 0.08 | 0.09 |
| Income Quality | 0.77 | 1.42 | -1.44 | 0.91 | 0.89 |
Currency in USD
